logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Staphylococcus Aureus Infection

    Medications for Staphylococcus Aureus Infection

    FiltersReset Filters
    4 results

    • daptomycin

      (daptomycin)
      Mylan Institutional LLC
      Usage: Daptomycin for injection is indicated for treating complicated skin and skin structure infections in adults and pediatric patients (1-17 years) caused by susceptible Gram-positive bacteria, and for Staphylococcus aureus bloodstream infections (bacteremia) in both adult and pediatric patients. Not recommended for pneumonia or left-sided infective endocarditis.

    • daptomycin

      (daptomycin)
      Mylan Institutional LLC
      Usage: Daptomycin for injection is indicated for treating complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bloodstream infections (bacteremia) in adults and pediatric patients (1-17 years). It is not recommended for pneumonia or left-sided infective endocarditis and should not be used in patients younger than 1 year.

    • daptomycin

      (DAPTOMYCIN)
      Meitheal Pharmaceuticals Inc.
      Usage: Daptomycin for Injection is indicated for treating complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bloodstream infections (bacteremia) in adults and pediatric patients aged 1 to 17. It is not recommended for pneumonia or left-sided infective endocarditis, and usage is limited in patients under 1 year.

    • zevtera

      (ceftobiprole medocaril sodium)
      La Jolla Pharmaceutical Company
      Usage: ZEVTERA is indicated for treating adult patients with Staphylococcus aureus bloodstream infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in pediatric patients (3 months to <18 years) caused by susceptible bacteria, including methicillin-resistant strains.